Nexus Pharmaceuticals Revenue and Competitors

Chicago, IL USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Nexus Pharmaceuticals's estimated annual revenue is currently $40.6M per year.(i)
  • Nexus Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • Nexus Pharmaceuticals has 202 Employees.(i)
  • Nexus Pharmaceuticals grew their employee count by 21% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$10.7M5356%N/AN/A
#2
$70.4M3501%N/AN/A
#3
$23.9M11913%$35MN/A
#4
$12.7M63-3%N/AN/A
#5
$5.4M27-25%N/AN/A
#6
$9.2M46-2%N/AN/A
#7
$35.3M3746%$289.7MN/A
#8
$7.2M36-23%N/AN/A
#9
$13.9M698%N/AN/A
#10
$186.3M92719%N/AN/A
Add Company

Nexus Pharmaceuticals, Inc. is a niche Generic pharmaceutical company located in 175 E Hawthorn Pkwy, Vernon Hills, Illinois, United States.

keywords:N/A

N/A

Total Funding

202

Number of Employees

$40.6M

Revenue (est)

21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Nexus Pharmaceuticals News

2022-04-17 - Trisenox (arsenic trioxide) Market Size 2022 Segments ...

Trisenox (arsenic trioxide) Market Size 2022 Segments, Competitors Strategy, Regional Analysis, Key Players |Teva, Fresenius Kabi, Nexus Pharmaceuticals,.

2022-04-17 - Isoprenaline Market Size, Outlook And Forecast | Novartis ...

... Marathon Pharmaceuticals, Bausch Health Companies, Pfizer, Sanofi, Sterling-Winthrop, Cipla USA, Amneal Biosciences, Nexus Pharmaceuticals .

2022-04-13 - Nexus Pharmaceuticals Announces Launch of Erythromycin ...

Nexus Pharmaceuticals, a US-based healthcare company and certified diverse supplier, specializes in innovative processes to make difficult-to-...

2019-09-08 - Wetlands rezoned to make way for pharmaceutical facility

During a special meeting, the board voted 5-0 to rezone two wetland areas to the west and south of the property for the Nexus Pharmaceuticals ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$32.5M2047%N/A
#2
$56.2M2245%N/A
#3
$68.5M248-2%N/A
#4
$78.1M2630%N/A
#5
$65.2M289-8%N/A